Testing a drug to improve heart imaging
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study tests if a drug can help suppress sugar uptake in the heart for clearer imaging. It may help researchers understand how to better see heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have no history of heart disease, high blood pressure, high cholesterol, diabetes, heart failure, coronary artery disease, heart surgery, or irregular heartbeats.
- You must have no chronic liver or kidney disease.
- You must not be pregnant or breastfeeding.
- You must not be taking diuretics (water pills) for any reason.
- You must have adequate kidney function (eGFR greater than 30).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if rilonacept can help people with cardiac sarcoidosis, a condition where inflammation affects the heart. You may join if you have active inflammation on a PET scan despite standard treatments.
This study checks whether a special heart scan called PET/MRI can predict how sarcoidosis may affect your heart. It may help doctors better estimate heart risk and plan follow-up based on scan findings.
This trial studies a treatment approach for people with active cardiac sarcoidosis, confirmed by specific heart rhythm/heart function problems and a PET scan. It may help by targeting the active inflammation driving heart conduction problems, rhythm events, or weak heart pumping.
This study tests whether a tracing agent called tilmanocept can help doctors see inflammation in the heart caused by sarcoidosis. It may provide a new way to diagnose and monitor cardiac sarcoidosis without invasive procedures.
This study tests if a special PET scan with 64Cu-DOTATATE can detect inflammation in the heart caused by sarcoidosis. It may help diagnose heart sarcoidosis more accurately in people with symptoms or known disease.
This trial tests a common diabetes drug (SGLT2 inhibitor) to see if it helps people with nonobstructive hypertrophic cardiomyopathy (HCM). The medicine may improve how your heart works and how well you can exercise.
Hear when a new Cardiac Sarcoidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.